NASDAQ:CLSD
Clearside BioMedical, Inc Stock News
$1.33
+0.0200 (+1.53%)
At Close: May 20, 2024
Analysts Estimate Clearside Biomedical, Inc. (CLSD) to Report a Decline in Earnings: What to Look Out for
03:47pm, Monday, 10'th May 2021
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Presentations support proprietary suprachoroidal space delivery platform and programs Presentations support proprietary suprachoroidal space delivery platform and programs
Clearside Biomedical to Report First Quarter 2021 Financial Results and Provide Corporate Update on Monday, May 17, 2021
07:05am, Tuesday, 04'th May 2021
ALPHARETTA, Ga., May 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vis
ALPHARETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi
Clearside Biomedical to Present at the Needham Virtual Healthcare Conference and Wet AMD & DME Drug Development Summit
07:05am, Monday, 05'th Apr 2021
ALPHARETTA, Ga., April 05, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve v
Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q4 2020 Results - Earnings Call Transcript
09:57pm, Wednesday, 10'th Mar 2021
Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q4 2020 Results - Earnings Call Transcript
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Lags Revenue Estimates
06:11pm, Wednesday, 10'th Mar 2021
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -7.69% and -98.90%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for th
Earnings Preview: Clearside Biomedical, Inc. (CLSD) Q4 Earnings Expected to Decline
01:38pm, Wednesday, 03'rd Mar 2021
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Initial Safety Data from First Cohort Expected Mid-2021 -
Clearside Biomedical to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 10, 2021
07:05am, Wednesday, 24'th Feb 2021
ALPHARETTA, Ga., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi
Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2021
07:05am, Tuesday, 23'rd Feb 2021
ALPHARETTA, Ga., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi
Circling Back On Clearside Biomedical
11:55am, Monday, 22'nd Feb 2021
For Clearside Biomedical, the onboarding of a new contract manufacturer should finally put its CRL issues for ocular therapy XIPERE in the rearview mirror. This move should pave the way for an NDA res
ALPHARETTA, Ga., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi
Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting
07:05am, Monday, 08'th Feb 2021
- Proprietary suprachoroidal injection platform demonstrates broad applicability across multiple retinal disorders -
Clearside Biomedical's (CLSD) Shares March Higher, Can It Continue?
06:04am, Tuesday, 02'nd Feb 2021
As of late, it has definitely been a great time to be an investor in Clearside Biomedical (CLSD).
